Highly Galactosylated Anti-CD20 (Rituximab) Antibody (CAT#: BioBet-GA-001ZP) Datasheet

MS4A1

membrane spanning 4-domains A1

This gene encodes a member of the membrane-spanning 4A gene family. Members of this nascent protein family are characterized by common structural features and similar intron/exon splice boundaries and display unique expression patterns among hematopoietic cells and nonlymphoid tissues. This gene encodes a B-lymphocyte surface molecule which plays a role in the development and differentiation of B-cells into plasma cells. This family member is localized to 11q12, among a cluster of family members. Alternative splicing of this gene results in two transcript variants which encode the same protein.

B1; S7; Bp35; CD20; CVID5; MS4A2; LEU-16

Plasma membrane

Its related pathways are Hematopoietic cell lineage and Hematopoietic Stem Cells and Lineage-specific Markers.

b lymphocyte-specific membrane protein, which is involved in the regulation of cellular calcium influx necessary for the development, differentiation and activation of b lymphocytes (PubMed:3925015, PubMed:7684739, PubMed:12920111). After activation of b-cell receptor/BCR, it acts as a component of stored and operated calcium (SOC) channels to promote calcium influx (PubMed:7684739, PubMed:12920111, PubMed:18474602).

Cancer antibody; Developmental Biology antibody; Immune System antibody; B cell Marker antibody; Immature B Cell Marker antibody; Inflammatory Cell Marker antibody; Tumor-infiltrating Lymphocyte Study antibody

Phosphorylated. Might be functionally regulated by protein kinase(s).

Protein Based Therapies
Monoclonal antibody (mAb)

IgG1

Rituximab

Mouse

Human

Rituximab is a chimeric mouse / human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes.

Non-Hodgkin's Lymphoma (NHL)
Chronic Lymphocytic Leukemia (CLL)
Rheumatoid Arthritis (RA)
Granulomatosis with Polyangiitis (GPA)
Moderate to severe Pemphigus Vulgaris (PV) in adult patients

rituximab-abbs
rituximab-pvvr

Similar to the parental antibody rituximab, glycoengineered ADCC-enhancement rituximab binds to the cell surface protein CD20 and enhances direct cell death and ADCC / ADCP effect. It tends to primarily affect malignant B cells with the highest CD20 levels.
There is evidence that when rituximab Fc binds to NK cell surface receptors, the success rate of killing cells reaches 80%. Therefore, the ADCC effect is the core mechanism by which rituximab works.

Rituximab was approved for medical use in 1997 to treat certain autoimmune diseases and cancer. By destroying CD20 that is present on the surface of B cells of the immune system, rituximab is mainly used to treat diseases characterized by excessive B cells, excessive B cell activity, or abnormal B cell function. It is also used for non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura, pemphigus vulgaris, myasthenia gravis, etc.

Rituximab is used to treat cancers of the white blood cell system, such as leukemia and lymphoma, including non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and the major lymphocyte subtype of Hodgkin's lymphoma.

There is evidence that rituximab is an effective treatment for rheumatoid arthritis. Rituximab has been widely used to treat a variety of other autoimmune diseases, including multiple sclerosis, systemic lupus erythematosus, chronic inflammatory demyelinating polyneuropathy, and autoimmune anemia.